Joel S. Marcus - Feb 26, 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Director
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Feb 26, 2024
Transactions value $
-$9,575
Form type
4
Date filed
2/27/2024, 07:57 PM
Previous filing
Jan 12, 2024
Next filing
Apr 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $869K +20K +68.42% $43.45 49.2K Feb 26, 2024 Direct
transaction ITCI Common Stock Options Exercise $930K +16.8K +34.04% $55.48 66K Feb 26, 2024 Direct
transaction ITCI Common Stock Sale -$568K -8.37K -12.69% $67.83 57.6K Feb 26, 2024 Direct F1
transaction ITCI Common Stock Sale -$1.22M -17.7K -30.65% $69.07 40K Feb 26, 2024 Direct F2
transaction ITCI Common Stock Sale -$20.8K -299 -0.75% $69.60 39.7K Feb 26, 2024 Direct F3
holding ITCI Common Stock 10K Feb 26, 2024 See Footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -20K -100% $0.00* 0 Feb 26, 2024 Common Stock 20K $43.45 Direct F5
transaction ITCI Stock Option (right to buy) Options Exercise $0 -16.8K -100% $0.00* 0 Feb 26, 2024 Common Stock 16.8K $55.48 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.53 to $68.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.53 to $69.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.53 to $69.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F5 All shares underlying this option have vested.